Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Summary

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Atrial Fibrillation (AF)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

65 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Anthos Therapeutics, Inc.

Last updated on ClinicalTrials.gov

July 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites